Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15360212 | 0.92 | SYK (0.58) | SYKROCK1ROCK2FLT3MAPK14 | |
| SCHEMBL15360214 | 0.88 | SYK (0.43) | SYKROCK1ROCK2KCNH2FLT3 | |
| SCHEMBL30775338 | 0.86 | SYK (0.48) | SYKCHRNB2CHRNA4PRKCZROCK1 | |
| SCHEMBL30775266 | 0.85 | SYK (0.47) | SYKCHRNB2CHRNA4PRKCZROCK1 | |
| SCHEMBL30775276 | 0.85 | SYK (0.47) | SYKCHRNB2CHRNA4PRKCZROCK1 | |
| SCHEMBL30757155 | 0.85 | SYK (0.52) | SYKCHRNB2CHRNA4PRKCZROCK1 | |
| SCHEMBL26987228 | 0.85 | SYK (0.52) | SYKCHRNB2CHRNA4PRKCZROCK1 | |
| SCHEMBL27125336 | 0.85 | SYK (0.52) | SYKCHRNB2CHRNA4PRKCZROCK1 | |
| SCHEMBL30775340 | 0.83 | SYK (0.46) | SYKCHRNB2CHRNA4PRKCZROCK1 | |
| SCHEMBL30775406 | 0.82 | HRH4 (0.52) | SYKCHRNB2CHRNA4PRKCZROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | SYK 4838/4885CHRNB2 3816/4885CHRNA4 4788/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | SYK 4838/4885CHRNB2 3816/4885CHRNA4 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.